more from bloomberg forest laboratories inc said fiscal second quarter profit increased percent on demand for its two biggest selling medicines net income for the quarter ended sept rose to million , or cents a share , from million , or cents , a year earlier , reflecting sales of the lexapro antidepressant and namenda for alzheimer 's disease , new york based forest said today in a statement the profit beat analysts' estimates sales jumped percent for lexapro and percent for namenda , and the two drugs accounted for percent of forest 's revenue for the quarter , the company said forest is developing and licensing new drugs to reduce its reliance on lexapro and namenda the issue for forest is , can the company sustain this kind of growth ? '' said timothy chiang , an analyst at ftn midwest securities corp in new york , in a telephone interview today certainly , the company 's results were better than my forecasts , but i still have a longer term view on the stock '' chiang rates forest shares neutral'' and does n't own any second quarter revenue for forest increased percent to million from million a year earlier sales of lexapro climbed to million , while namenda reached million forest won a federal court ruling in july protecting lexapro , which it started selling in , from generic competition from teva pharmaceutical industries ltd , based in petah tikva , israel while teva ca n't copy lexapro before , teva has started selling a generic form of zoloft , an antidepressant made by new york based pfizer inc , and some drug industry analysts have said the generic might cut into how many new patients buy lexapro we have not seen any meaningful change in prescribing patterns for lexapro at this point , '' goodman said forest licensed lexapro from copenhagen based h lundbeck a s and acquired rights to namenda from the merz group , based in frankfurt am main , germany namenda 's patents begin expiring in , and forest may face generic competition for the drug as early as , chiang said around , , the company could be dealing with a cliff , falling off a cliff , in terms of its revenue base , '' chiang said they 're working hard to put together a late stage pipeline '' hey , how about making another ssri ? there are just not enough of those on the market or , better yet , try a dual norepinephrine serotonin reuptake inhibitor and market it very aggressively that apparently worked for cymbalta just ask lilly it seems like forest is overly dependent on these two psych meds , and i would think that given namenda s very modest benefits , there couldn t be more too much more growth for it then again , there are many products that offer few benefits which end up being widely used take neurontin , for example link to bloomberg post here